A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis

NCT03163966 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

248

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis, DMARD-naive and Early Disease Patients

Interventions

DRUG: CR6086
DRUG: Methotrexate
DRUG: Placebo

Sponsor

Rottapharm Biotech